Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15276 - 15300 of 15759 in total
Dipraglurant has been used in trials studying the treatment of Parkinson's Disease. It is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).
Investigational
Diminazene, also known as Diminazine, 4,4'-(Diazoamino)benzamidine, 4,4'-(1-triazene-1,3-diyl)bis-benzenecarboximidamide, diminazine aceturate, or Diminazene aceturate, is a trypanocidal agent. Major brands of Diminazene are Berenil, Pirocide, Ganasag, and Azidin. This substance is a solid. This compound belongs to the phenylhydrazines. These are compounds containing a phenylhydrazide moiety, which consists of a hydrazide substituent...
Experimental
Matched Description: … Major brands of Diminazene are Berenil, Pirocide, Ganasag, and Azidin. This substance is a solid. ... HTH-type transcriptional regulator QacR, trypsin-1, amiloride-sensitive amine oxidase [copper-containing], and
RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
Investigational
Matched Description: … neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and
CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
Investigational
Matched Description: … dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and
Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity . It is currently in clinical trials for the treatment of a wide range of tumors.
Investigational
Matched Description: … Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity …
ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C).
Investigational
Matched Description: … clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and
EC-0652 is under investigation in clinical trial NCT02202447 (Phase 1 of EC1169 In Patients With Recurrent MCRPC).
Investigational
Matched Iupac: … phenylethyl]carbamoyl}-2-phenylethyl]carbamoyl}heptyl)carbamoyl]-1-carboxypropyl]carbamoyl}amino)pentanedioic acid
Investigational
Matched Iupac: … -1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-yl]oxidanesulfonic acid
Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML).
Investigational
Matched Iupac: … -methyloxan-2-yl]oxy}cyclohexyl]oxy}-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}propanoic acid
Matched Description: … antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and
Experimental
OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.
Investigational
OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
Investigational
Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery).
Investigational
Matched Iupac: … amino-1-[(2S)-2-{[(1S)-1-carbamoyl-2-methylpropyl]carbamoyl}pyrrolidin-1-yl]-1-oxohexan-2-yl]carbamoyl}methyl ... hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]butanoic acid
Matched Description: … Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple …
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
Matched Description: … AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to …
Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).
Investigational
Matched Iupac: … 2-[(4aR)-1-(4-fluorophenyl)-6-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-1H,4H,4aH,5H,6H,7H,8H-pyrido[3,4-f …
Displaying drugs 15276 - 15300 of 15759 in total